185 related articles for article (PubMed ID: 18289051)
1. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
2. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
3. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
4. ADAM10: a new player in breast cancer progression?
Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ
Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334
[TBL] [Abstract][Full Text] [Related]
5. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
6. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
7. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein.
Moss ML; Powell G; Miller MA; Edwards L; Qi B; Sang QX; De Strooper B; Tesseur I; Lichtenthaler SF; Taverna M; Zhong JL; Dingwall C; Ferdous T; Schlomann U; Zhou P; Griffith LG; Lauffenburger DA; Petrovich R; Bartsch JW
J Biol Chem; 2011 Nov; 286(47):40443-51. PubMed ID: 21956108
[TBL] [Abstract][Full Text] [Related]
8. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.
Grabowska MM; Sandhu B; Day ML
Cell Signal; 2012 Feb; 24(2):532-538. PubMed ID: 22024284
[TBL] [Abstract][Full Text] [Related]
9. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.
Woods N; Trevino J; Coppola D; Chellappan S; Yang S; Padmanabhan J
Oncotarget; 2015 Nov; 6(34):35931-48. PubMed ID: 26440150
[TBL] [Abstract][Full Text] [Related]
10. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
11. Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
Soundararajan R; Sayat R; Robertson GS; Marignani PA
Cancer Biol Ther; 2009 Nov; 8(21):2054-62. PubMed ID: 19783906
[TBL] [Abstract][Full Text] [Related]
12. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma.
Lee SB; Schramme A; Doberstein K; Dummer R; Abdel-Bakky MS; Keller S; Altevogt P; Oh ST; Reichrath J; Oxmann D; Pfeilschifter J; Mihic-Probst D; Gutwein P
J Invest Dermatol; 2010 Mar; 130(3):763-73. PubMed ID: 19865098
[TBL] [Abstract][Full Text] [Related]
13. ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin.
Schulz B; Pruessmeyer J; Maretzky T; Ludwig A; Blobel CP; Saftig P; Reiss K
Circ Res; 2008 May; 102(10):1192-201. PubMed ID: 18420943
[TBL] [Abstract][Full Text] [Related]
14. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
[TBL] [Abstract][Full Text] [Related]
15. Targeting ADAM10 in Cancer and Autoimmunity.
Smith TM; Tharakan A; Martin RK
Front Immunol; 2020; 11():499. PubMed ID: 32265938
[TBL] [Abstract][Full Text] [Related]
16. Targeting of retinal axons requires the metalloproteinase ADAM10.
Chen YY; Hehr CL; Atkinson-Leadbeater K; Hocking JC; McFarlane S
J Neurosci; 2007 Aug; 27(31):8448-56. PubMed ID: 17670992
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Kai Y; Peng W; Ling W; Jiebing H; Zhuan B
Biochem Biophys Res Commun; 2014 Jun; 448(3):308-14. PubMed ID: 24530397
[TBL] [Abstract][Full Text] [Related]
18. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10.
Lemieux GA; Blumenkron F; Yeung N; Zhou P; Williams J; Grammer AC; Petrovich R; Lipsky PE; Moss ML; Werb Z
J Biol Chem; 2007 May; 282(20):14836-44. PubMed ID: 17389606
[TBL] [Abstract][Full Text] [Related]
19. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
20. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
